DIE European Medicines Agency (EMA) has begun reviewing the approval of the French manufacturer Sanofi for the coronavirus vaccine. “EMA will assess whether Vidprevtyn meets the usual EU efficacy, safety and quality standards,” the Amsterdam-based authority said on Tuesday. Sanofi and GlaxoSmithKline jointly developed Vidprevtyn.
Unlike mRNA vaccines Biological Technology Moderna does not require extremely low storage temperatures, which will make logistics and transportation easier. Like most coronavirus vaccines, two doses are required for full protection.
The decision to start the so-called rolling review was based on preliminary results, “showing that the vaccine will trigger the production of antibodies, which (…) can help prevent disease,” EMA said. They will “evaluate more data as soon as it becomes available to determine whether the benefits outweigh the risks.” She did not give a more precise timetable.
inside I Vaccines from BioNTech/Pfizer, Moderna, AstraZeneca and Johnson & Johnson are now approved. Russia’s Sputnik V and China’s vaccine Sinovac are also under review.
